Yuanzhi Bian

Mr. Yuanzhi Bian

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2023 in Viruses
Verified
Journal Article
Open access
PDF file
YBYuanzhi Bian
Yuanzhi Bian
DWDebra L. Walter
Debra L. Walter
Chenming ZhangChenming Zhang
Chenming Zhang
Interferon-γ (IFN-γ) is a cytokine that plays an important role in immune regulation, especially in the activation and differentiation of immune cells. Toll-like receptors (TLRs) are a family of pattern-recognition receptors that sense structural motifs related to pathogens and alert immune cells to the invasion. Both IFN-γ and TLR agonists have been used as immunoadjuvants to augment the efficacy of cancer immunotherapies and vaccines against infectious diseases or psychoactive compounds. In this study, we aimed to explore the potential of IFN-γ and TLR agonists being applied simultaneously to boost dendritic cell activation and the subsequent antigen presentation. In brief, murine dendritic cells were treated with IFN-γ and/or the TLR agonists, polyinosinic–polycytidylic acid (poly I:C), or resiquimod (R848). Next, the dendritic cells were stained for an activation marker, a cluster of differentiation 86 (CD86), and the percentage of CD86-positive cells was measured by flow cytometry. From the cytometric analysis, IFN-γ efficiently stimulated a considerable number of the dendritic cells, while the TLR agonists by themselves could merely activate a few compared to the control. The combination of IFN-γ with poly I:C or R848 triggered a higher amount of dendritic cell activation than IFN-γ alone. For instance, 10 ng/mL IFN-γ with 100 µg/mL poly I:C achieved 59.1% cell activation, which was significantly higher than the 33.4% CD86-positive cells obtained by 10 ng/mL IFN-γ. These results suggested that IFN-γ and TLR agonists could be applied as complementary systems to promote dendritic cell activation and antigen presentation. There might be a synergy between the two classes of molecules, but further investigation is warranted to ascertain the interaction of their promotive activities.

18 August 2024 in Biomaterials
Verified
Journal Article
Closed access
DWDebra L. Walter
Debra L. Walter
YBYuanzhi Bian
Yuanzhi Bian
HHHe Hu
He Hu
FHFatima A. Hamid
Fatima A. Hamid
KRKobra Rostamizadeh
Kobra Rostamizadeh
Chenming ZhangChenming Zhang
Chenming Zhang

20 September 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YBYuanzhi Bian
Yuanzhi Bian
QCQiaoqiao Ci
Qiaoqiao Ci
XLXin Luo
Xin Luo
Chenming ZhangChenming Zhang
Chenming Zhang
Substance use disorders (SUDs) remain a major global health challenge with limited treatment options and high relapse rates. Vaccines that induce drug-sequestering antibodies have shown promise, but their efficacy is hindered by the poor immunogenicity of small-molecule haptens. Adjuvants, substances that enhance immune responses, are critical for overcoming this limitation and improving vaccine efficacy. This review synthesizes over two decades of preclinical and clinical research to guide rational adjuvant design for SUD vaccines. Five major adjuvant classes are examined: aluminum-salt adjuvants, emulsion adjuvants, toll-like receptor (TLR) agonists, protein immunopotentiators, and cytokine modulators. Their physicochemical properties, innate immune activation profiles, and applications in nicotine, stimulant, and opioid vaccines are discussed. Comparative analyses reveal pronounced drug-specific and carrier-specific variability. Case studies illustrate the superior performance of a complementary TLR-agonist pair in a nicotine nanovaccine versus its limited effect in oxycodone vaccines. They also reveal the differential efficacy of an oil-in-water emulsion adjuvant across antigen types. Four principles emerge: (i) no adjuvant is universally optimal; (ii) drug pharmacology influences immune signaling; (iii) adjuvant-carrier compatibility is important; (iv) complementary adjuvant pairings often outperform single agents. These insights support a precision-vaccinology paradigm that tailors adjuvant strategies to each drug class and the delivery vehicle, advancing the development of next-generation SUD vaccines.

5 July 2025 in International Journal of Toxicology
Verified
Journal Article
Closed access
DWDebra Walter
Debra Walter
QCQiaoqiao Ci
Qiaoqiao Ci
HHHe Hu
He Hu
RDRiley DeHority
Riley DeHority
Jonathan HinckleyJonathan Hinckley
Jonathan Hinckley
Chenming ZhangChenming Zhang
Chenming Zhang
A nanoparticle-based immunization strategy offers a promising treatment for opioid use disorder (OUD). This study tested the in vivo safety of subunit keyhole limpet hemocyanin-loaded lipid–PLGA hybrid nanoparticles (sKLH-hNPs) as a nanocarrier for OUD vaccine in adult male BALB/c mice by subcutaneous administration at an effective low dose (60 μg) and a dose 5-fold higher (300 μg), with cohorts of animals (n = 10/group, including controls) observed and evaluated for behavioral changes. At 3, 14, 28, and 56 days after dosing, mice (n = 3/dose) were sacrificed, and serum was collected for evaluation of electrolytes, minerals, proteins, liver function, renal function, and energy metabolism. Histological examination included all critical organs, gastrocnemius muscle, and skin from the site of injection. For behavioral evaluation, home cage, open field, and reflex observations were compared among the groups. Results demonstrated no statistical differences among the groups, with the exception of respirations observed in the home cage (O-RESP) on Day 3 ( P = 0.03). There was no evidence of any effect of the test product on energy (glucose, cholesterol, triglycerides) or mineral metabolism (phosphorus, calcium) and hepatic function (urea nitrogen, albumin, total bilirubin), and no indication that the test agent caused liver injury, cholestasis, muscle damage, or acid-base imbalance. Histological analysis in control and treated mice generally revealed no significant findings, although small areas of hemorrhage, lymphocyte infiltration, and thick areas in the subcutis were noted in a subset of samples from both control and treated animals. These experiments suggest that the nanoparticle-based product would be safe for vaccines treating OUD.

8 April 2026 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
ZQZhen Qian
Zhen Qian
TKTom Kasputis
Tom Kasputis
QCQiaoqiao Ci
Qiaoqiao Ci
YBYuanzhi Bian
Yuanzhi Bian
Chenming ZhangChenming Zhang
Chenming Zhang

11 October 2025 in Biomaterials
Verified
Journal Article
Closed access
YBYuanzhi Bian
Yuanzhi Bian
QCQiaoqiao Ci
Qiaoqiao Ci
KRKobra Rostamizadeh
Kobra Rostamizadeh
CMCourtney Marecki
Courtney Marecki
FHFatima A. Hamid
Fatima A. Hamid
Chenming ZhangChenming Zhang
Chenming Zhang